Pharma Talk John Mack
-
- Negócios
John Mack (previously Pharmaguy) was a thought leader in pharmaceutical marketing with more than 30 years experience in the digital space, including interactive game design, computer-based learning, drug website development, ehealth ethics, and social media. He has retired from this role and is now a leader in municipal government: Newtown Township PA Supervisor
-
The Misleading Marketing of "Low-T" Drugs
A conversation with Adriane Fugh-Berman, MD, Associate Professor at Georgetown University Medical Center and Director of PharmedOut. We discuss how the marketing of Androgel uses symptom quizzes to convince men and physicians that "low testosterone" is a medical condition that should be treated. We also discuss the dangerous side effects of testosterone treatment and the similarities with estrogen treatment side effects, which took 20 years to unveil.
-
The Forgotten eHealth Code of Ethics
Any research or effort designed to improve the quality of health information on the Internet must build upon the work already done by the creators of the international eHealth Code of Ethics, which is as relevant today as it was back in 2000.
-
AMA Struggles to Reign in Consumer Drug Ads
You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?
-
Counter Detailing Offers Redemption But Little Hope of Success
Do you hate your job in pharma? Perhaps, like a friend of mine, your position got eliminated after many years of loyal service. But it may be a blessing in disguise if the behavior of Big Pharma is more and more at odds with your personal values. If so, you have options for cleansing your soul.
-
Patient Centricity & Pharma’s Reputation
Patient Centricity used to be a buzzword in that it was often mentioned but seldom practiced by pharma companies. A lot of progress has been made in the past years to achieve patient centricity, but not all drug companies have had much success. Unfortunately, that has had a negative impact on the industry’s reputation
-
The Two Faces of FDA Regarding the Opioid Epidemic
The #FDA has a lot of hurdles to overcome in its effort to stem the #opioid crisis it helped to create. And it doesn’t help that Trump’s proposed Medicaid cuts will negatively impact funding for drug rehab treatment.